These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Multivariate modeling of cytochrome P450 3A4 inhibition. Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335 [TBL] [Abstract][Full Text] [Related]
65. In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms. Dmitriev AV; Rudik AV; Karasev DA; Pogodin PV; Lagunin AA; Filimonov DA; Poroikov VV Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33924315 [TBL] [Abstract][Full Text] [Related]
66. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Rochat B; Amey M; Gillet M; Meyer UA; Baumann P Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356 [TBL] [Abstract][Full Text] [Related]
67. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556 [TBL] [Abstract][Full Text] [Related]
68. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574 [TBL] [Abstract][Full Text] [Related]
69. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Spracklin DK; Thummel KE; Kharasch ED Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607 [TBL] [Abstract][Full Text] [Related]
70. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109 [TBL] [Abstract][Full Text] [Related]
71. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes. Lewis DF; Lake BG; Ito Y; Dickins M J Enzyme Inhib Med Chem; 2006 Aug; 21(4):385-9. PubMed ID: 17059170 [TBL] [Abstract][Full Text] [Related]
72. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091 [TBL] [Abstract][Full Text] [Related]
73. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202 [TBL] [Abstract][Full Text] [Related]
74. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules. McMasters DR; Torres RA; Crathern SJ; Dooney DL; Nachbar RB; Sheridan RP; Korzekwa KR J Med Chem; 2007 Jul; 50(14):3205-13. PubMed ID: 17559204 [TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030 [TBL] [Abstract][Full Text] [Related]
76. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553 [TBL] [Abstract][Full Text] [Related]
78. 5-Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide. Fradette C; Yamaguchi N; Du Souich P Br J Pharmacol; 2004 Feb; 141(3):407-14. PubMed ID: 14718257 [TBL] [Abstract][Full Text] [Related]
79. Prediction of Human Cytochrome P450 Inhibition Using a Multitask Deep Autoencoder Neural Network. Li X; Xu Y; Lai L; Pei J Mol Pharm; 2018 Oct; 15(10):4336-4345. PubMed ID: 29775322 [TBL] [Abstract][Full Text] [Related]
80. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]